Immunomodulatory therapy in non-infectious Uveitis: Current landscape, gaps, and future directions

Non-infectious uveitis (NIU) is a potentially sight-threatening intraocular inflammatory condition that may arise idiopathically or in association with systemic immune-mediated diseases. While corticosteroids remain essential for rapid suppression of inflammation, their long-term use is limited by s...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Agrawal, Rupesh (VerfasserIn) , Goh, Yun Yao (VerfasserIn) , Rojas-Carabali, William (VerfasserIn) , Cifuentes-González, Carlos (VerfasserIn) , Sanjay, Srinivasan (VerfasserIn) , Yu-Hor Thong, Bernard (VerfasserIn) , de-la-Torre, Alejandra (VerfasserIn) , Samson, Cesar Michael (VerfasserIn) , Biswas, Jyotirmay (VerfasserIn) , Finger, Robert P. (VerfasserIn) , Kempen, John H. (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: September 2025
In: Progress in retinal and eye research
Year: 2025, Jahrgang: 108, Pages: 1-35
ISSN:1873-1635
DOI:10.1016/j.preteyeres.2025.101380
Online-Zugang:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1016/j.preteyeres.2025.101380
Verlag, lizenzpflichtig, Volltext: https://www.sciencedirect.com/science/article/pii/S1350946225000539
Volltext
Verfasserangaben:Rupesh Agrawal, Yun Yao Goh, William Rojas-Carabali, Carlos Cifuentes-González, Srinivasan Sanjay, Bernard Yu-Hor Thong, Alejandra de-la-Torre, Cesar Michael Samson, Jyotirmay Biswas, Robert Patrick Finger, John H. Kempen

MARC

LEADER 00000naa a2200000 c 4500
001 193359408X
003 DE-627
005 20250820093503.0
007 cr uuu---uuuuu
008 250820s2025 xx |||||o 00| ||eng c
024 7 |a 10.1016/j.preteyeres.2025.101380  |2 doi 
035 |a (DE-627)193359408X 
035 |a (DE-599)KXP193359408X 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Agrawal, Rupesh  |e VerfasserIn  |0 (DE-588)1374300888  |0 (DE-627)1933594918  |4 aut 
245 1 0 |a Immunomodulatory therapy in non-infectious Uveitis  |b Current landscape, gaps, and future directions  |c Rupesh Agrawal, Yun Yao Goh, William Rojas-Carabali, Carlos Cifuentes-González, Srinivasan Sanjay, Bernard Yu-Hor Thong, Alejandra de-la-Torre, Cesar Michael Samson, Jyotirmay Biswas, Robert Patrick Finger, John H. Kempen 
264 1 |c September 2025 
300 |b Illustrationen 
300 |a 35 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Online veröffentlicht: 21. Juni 2025, Artikelversion: 4. Juli 2025 
500 |a Gesehen am 20.08.2025 
520 |a Non-infectious uveitis (NIU) is a potentially sight-threatening intraocular inflammatory condition that may arise idiopathically or in association with systemic immune-mediated diseases. While corticosteroids remain essential for rapid suppression of inflammation, their long-term use is limited by significant systemic and ocular side effects. Thus, immunomodulatory therapy (IMT)—including antimetabolites, calcineurin inhibitors, biologics, and emerging small molecules—has become central to achieving sustained control with a reduced corticosteroid burden in chronic cases. Despite a range of therapeutic options, significant challenges persist. Safe, remission-inducing treatments remain elusive; tapering strategies are poorly standardized; and evidence for optimal combinations or long-term outcomes remains limited. Recent registries, such as Programme for Ocular Inflammation and Infection Translational Research (PROTON) and Treatment Exit Options for Uveitis (TOFU), are beginning to address the unmet need for structured treatment exit frameworks. Moreover, advances in imaging and artificial intelligence may soon enable real-time monitoring of disease status and risk stratification, although the development of large, well-annotated cohorts to be subject to such analysis remains a key hurdle. This review summarizes the current role of IMT in the management of NIU, with an emphasis on corticosteroid-sparing strategies. We highlight the use of conventional immunosuppressants—including antimetabolites, calcineurin inhibitors, and alkylating agents—as well as newer biologic, smallmolecule, and interferon-based therapies. We outline where IMT fits within the broader treatment algorithm, discuss emerging evidence for earlier initiation, and explore future directions in targeted and personalized immunotherapy. We also explore future directions, including personalized approaches, biomarker-driven therapy, and the promise of AI-guided prediction models. 
650 4 |a Artificial intelligence 
650 4 |a Autoimmune disease 
650 4 |a Biologic agents 
650 4 |a Corticosteroids 
650 4 |a Disease-modifying antirheumatic drugs (DMARDs) 
650 4 |a Immunomodulatory therapy 
650 4 |a Non-infectious uveitis 
650 4 |a Ocular inflammation 
650 4 |a Personalized medicine 
700 1 |a Goh, Yun Yao  |e VerfasserIn  |4 aut 
700 1 |a Rojas-Carabali, William  |e VerfasserIn  |4 aut 
700 1 |a Cifuentes-González, Carlos  |e VerfasserIn  |4 aut 
700 1 |a Sanjay, Srinivasan  |e VerfasserIn  |4 aut 
700 1 |a Yu-Hor Thong, Bernard  |e VerfasserIn  |4 aut 
700 1 |a de-la-Torre, Alejandra  |e VerfasserIn  |4 aut 
700 1 |a Samson, Cesar Michael  |e VerfasserIn  |4 aut 
700 1 |a Biswas, Jyotirmay  |e VerfasserIn  |4 aut 
700 1 |a Finger, Robert P.  |d 1979-  |e VerfasserIn  |0 (DE-588)133279049  |0 (DE-627)539656488  |0 (DE-576)287511855  |4 aut 
700 1 |a Kempen, John H.  |e VerfasserIn  |4 aut 
773 0 8 |i Enthalten in  |t Progress in retinal and eye research  |d Amsterdam [u.a.] : Elsevier Science, 1994  |g 108(2025), Artikel-ID 101380, Seite 1-35  |h Online-Ressource  |w (DE-627)320473805  |w (DE-600)2008881-4  |w (DE-576)097188654  |x 1873-1635  |7 nnas  |a Immunomodulatory therapy in non-infectious Uveitis Current landscape, gaps, and future directions 
773 1 8 |g volume:108  |g year:2025  |g elocationid:101380  |g pages:1-35  |g extent:35  |a Immunomodulatory therapy in non-infectious Uveitis Current landscape, gaps, and future directions 
856 4 0 |u https://doi.org/10.1016/j.preteyeres.2025.101380  |x Verlag  |x Resolving-System  |z lizenzpflichtig  |3 Volltext 
856 4 0 |u https://www.sciencedirect.com/science/article/pii/S1350946225000539  |x Verlag  |z lizenzpflichtig  |3 Volltext 
951 |a AR 
992 |a 20250820 
993 |a Article 
994 |a 2025 
998 |g 133279049  |a Finger, Robert P.  |m 133279049:Finger, Robert P.  |d 60000  |d 61300  |e 60000PF133279049  |e 61300PF133279049  |k 0/60000/  |k 1/60000/61300/  |p 10 
999 |a KXP-PPN193359408X  |e 4759134336 
BIB |a Y 
SER |a journal 
JSO |a {"language":["eng"],"person":[{"role":"aut","given":"Rupesh","display":"Agrawal, Rupesh","family":"Agrawal"},{"role":"aut","given":"Yun Yao","display":"Goh, Yun Yao","family":"Goh"},{"family":"Rojas-Carabali","display":"Rojas-Carabali, William","role":"aut","given":"William"},{"display":"Cifuentes-González, Carlos","family":"Cifuentes-González","given":"Carlos","role":"aut"},{"display":"Sanjay, Srinivasan","family":"Sanjay","role":"aut","given":"Srinivasan"},{"role":"aut","given":"Bernard","display":"Yu-Hor Thong, Bernard","family":"Yu-Hor Thong"},{"family":"de-la-Torre","display":"de-la-Torre, Alejandra","given":"Alejandra","role":"aut"},{"display":"Samson, Cesar Michael","family":"Samson","given":"Cesar Michael","role":"aut"},{"family":"Biswas","display":"Biswas, Jyotirmay","role":"aut","given":"Jyotirmay"},{"role":"aut","given":"Robert P.","display":"Finger, Robert P.","family":"Finger"},{"family":"Kempen","display":"Kempen, John H.","given":"John H.","role":"aut"}],"id":{"doi":["10.1016/j.preteyeres.2025.101380"],"eki":["193359408X"]},"relHost":[{"title":[{"title_sort":"Progress in retinal and eye research","title":"Progress in retinal and eye research"}],"note":["Gesehen am 21.02.20"],"origin":[{"publisher":"Elsevier Science","dateIssuedKey":"1994","dateIssuedDisp":"1994-","publisherPlace":"Amsterdam [u.a.]"}],"pubHistory":["Nachgewiesen 13.1994 -"],"disp":"Immunomodulatory therapy in non-infectious Uveitis Current landscape, gaps, and future directionsProgress in retinal and eye research","type":{"media":"Online-Ressource","bibl":"periodical"},"recId":"320473805","physDesc":[{"extent":"Online-Ressource"}],"id":{"eki":["320473805"],"zdb":["2008881-4"],"issn":["1873-1635"]},"language":["eng"],"part":{"volume":"108","text":"108(2025), Artikel-ID 101380, Seite 1-35","extent":"35","pages":"1-35","year":"2025"},"titleAlt":[{"title":"Retinal and eye research"}]}],"recId":"193359408X","physDesc":[{"extent":"35 S.","noteIll":"Illustrationen"}],"name":{"displayForm":["Rupesh Agrawal, Yun Yao Goh, William Rojas-Carabali, Carlos Cifuentes-González, Srinivasan Sanjay, Bernard Yu-Hor Thong, Alejandra de-la-Torre, Cesar Michael Samson, Jyotirmay Biswas, Robert Patrick Finger, John H. Kempen"]},"type":{"bibl":"article-journal","media":"Online-Ressource"},"title":[{"subtitle":"Current landscape, gaps, and future directions","title_sort":"Immunomodulatory therapy in non-infectious Uveitis","title":"Immunomodulatory therapy in non-infectious Uveitis"}],"origin":[{"dateIssuedKey":"2025","dateIssuedDisp":"September 2025"}],"note":["Online veröffentlicht: 21. Juni 2025, Artikelversion: 4. Juli 2025","Gesehen am 20.08.2025"]} 
SRT |a AGRAWALRUPIMMUNOMODU2025